KIDNEY INT:血液透析儿童血红蛋白12g/dl以上与心血管疾病死亡率增加无关!!!

2016-11-28 haofan MedSci原创

对进行血液透析的儿童,血红蛋白12g/dl以上与心血管疾病就诊率、死亡率增加不存在相关性,或与心血管疾病的全因死亡率和心血管疾病相关的住院治疗率无关。

成年肾衰患者进行长期血液透析过程中,红细胞生成刺激剂使血红蛋白浓度达到12g/dl以上可导致心血管事件和死亡率的增加,但这在儿童群体中可能不会如此。


近日,肾脏病领域权威杂志kidney international上发表了一篇来自美国明尼苏达大学共济会儿童医院的Michelle N.Rheault医生及其团队的研究文章,旨在进行血液透析的儿童其血红蛋白浓度达到12g/dl以上是否会导致心血管事件和死亡率的增加。

研究人员在儿童患者中进行了一项回顾性队列研究,这些患儿来自医疗保险和医疗补助服务中心的终末期肾脏疾病(ESRD)临床措施(CPM)项目(2000年至2008年)和美国肾脏数据系统。研究人员从临床表现和指标数据中确定了患儿血红蛋白浓度,并从每年1月1日开始至第二年1月1日,研究人员对患儿随访1年时间。研究人员在随访之初,确定了结局事件(死亡率、住院率和心血管事件),在该模型中,研究人员对纳入研究的1569名儿童的人口学和临床特征进行了调整。

血红蛋白为12g/dl以上组年龄较大,而且终末期肾病的持续时间较短,进行肾脏移植的患儿也较多。因充血性心力衰竭、心肌病和心脏瓣膜病住院和门诊治疗的患者在血红蛋白低于10g/dl组,而且随着血红蛋白浓度的增加这些疾病诊断的频率反而降低。血红蛋白12g/dl以上组患儿全因死亡率的危险比(0.33,95%可信区间为0.14–0.81)和调整后的相对的全因住院率(0.81,95%可信区间为0.74-0.89)均显著降低。因心血管疾病住院患儿在血红蛋白低于10g/dl组(1.31,95%可信区间为1.05–1.64)显著增加。

因此,对进行血液透析的儿童,血红蛋白12g/dl以上与心血管疾病就诊率、死亡率增加不存在相关性,或与心血管疾病的全因死亡率和心血管疾病相关的住院治疗率无关。

原始出处:

Michelle N.Rheault,et al. Hemoglobin of 12 g/dl and above is not associated with increased cardiovascular morbidity in children on hemodialysis. kidney international. 16 November 2016.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=160567, encodeId=96e416056e2e, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Dec 06 06:50:48 CST 2016, time=2016-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262473, encodeId=a67b12624e3b3, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Wed Nov 30 03:30:00 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498097, encodeId=be72149809e51, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Nov 30 03:30:00 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602982, encodeId=91df160298210, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Wed Nov 30 03:30:00 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158975, encodeId=56e61589e539, content=可以了解最新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b4c1651704, createdName=1ddcba5em94(暂无匿称), createdTime=Tue Nov 29 21:50:10 CST 2016, time=2016-11-29, status=1, ipAttribution=)]
    2016-12-06 李东泽

    很好,不错,以后会多学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=160567, encodeId=96e416056e2e, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Dec 06 06:50:48 CST 2016, time=2016-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262473, encodeId=a67b12624e3b3, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Wed Nov 30 03:30:00 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498097, encodeId=be72149809e51, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Nov 30 03:30:00 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602982, encodeId=91df160298210, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Wed Nov 30 03:30:00 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158975, encodeId=56e61589e539, content=可以了解最新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b4c1651704, createdName=1ddcba5em94(暂无匿称), createdTime=Tue Nov 29 21:50:10 CST 2016, time=2016-11-29, status=1, ipAttribution=)]
    2016-11-30 habb
  3. [GetPortalCommentsPageByObjectIdResponse(id=160567, encodeId=96e416056e2e, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Dec 06 06:50:48 CST 2016, time=2016-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262473, encodeId=a67b12624e3b3, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Wed Nov 30 03:30:00 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498097, encodeId=be72149809e51, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Nov 30 03:30:00 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602982, encodeId=91df160298210, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Wed Nov 30 03:30:00 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158975, encodeId=56e61589e539, content=可以了解最新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b4c1651704, createdName=1ddcba5em94(暂无匿称), createdTime=Tue Nov 29 21:50:10 CST 2016, time=2016-11-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=160567, encodeId=96e416056e2e, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Dec 06 06:50:48 CST 2016, time=2016-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262473, encodeId=a67b12624e3b3, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Wed Nov 30 03:30:00 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498097, encodeId=be72149809e51, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Nov 30 03:30:00 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602982, encodeId=91df160298210, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Wed Nov 30 03:30:00 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158975, encodeId=56e61589e539, content=可以了解最新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b4c1651704, createdName=1ddcba5em94(暂无匿称), createdTime=Tue Nov 29 21:50:10 CST 2016, time=2016-11-29, status=1, ipAttribution=)]
    2016-11-30 gwc389
  5. [GetPortalCommentsPageByObjectIdResponse(id=160567, encodeId=96e416056e2e, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Dec 06 06:50:48 CST 2016, time=2016-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262473, encodeId=a67b12624e3b3, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Wed Nov 30 03:30:00 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498097, encodeId=be72149809e51, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Nov 30 03:30:00 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602982, encodeId=91df160298210, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Wed Nov 30 03:30:00 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158975, encodeId=56e61589e539, content=可以了解最新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b4c1651704, createdName=1ddcba5em94(暂无匿称), createdTime=Tue Nov 29 21:50:10 CST 2016, time=2016-11-29, status=1, ipAttribution=)]
    2016-11-29 1ddcba5em94(暂无匿称)

    可以了解最新进展

    0

相关资讯

JACC:低胆固醇吸收的血液透析患者或可受益于阿托伐他汀治疗

血液透析患者对胆固醇有很高的吸收率,抑制胆固醇合成的血液透析患者可能受益于阿托伐他汀治疗。 本研究测定肠道胆固醇吸收率是否有助于预测血液透析患者服用他汀类药物的有效性。 在这项德国糖尿病血透(4D)研究(German Diabetes and Dialysis study)中,收纳入了1030例参与者,随机分配为两组,阿托伐他汀20mg/日组(n = 519)或安慰剂组(n = 511)。主要

Circulation:新发房颤血液透析患者死亡和脑卒中的风险

口服抗凝剂(OAC)是否可以用于治疗心房颤动(AF)患者血液透析,由于有关的风险效益评估的不确定性,仍然是有争议的。本研究的目的是调查与那些无心律失常患者相比,正在接受血液透析的新发AF患者的缺血性中风风险。在1998-2011期间,这一全国性,以人群为基础,倾向得分匹配队列研究使用来自台湾的全民健康保险研究资料库数据,患者为新发的非瓣膜性房颤需要血液透析的患者,匹配对象为没有心律失常的人群。临床

NEJM:一例因不按期行血液透析治疗导致高钾血症的案例报道

患者男性,48岁,既往患有终末期肾脏病史和甲状旁腺切除手术史,1个月前因没有按疗程准时行血液透析治疗后出现疲劳和弥漫性肌肉疼痛,而被紧急送往急诊科就诊。

重磅:32岁科学家发明血液癌细胞“透析”技术,真是神了!

癌症是世界上最致命的疾病之一,尽管人类已经为之奋战数十年,并取得了较大的进展,但在癌症防治的临床应用上,仍缺少切实有效的新方法。今年《麻省理工学院技术评论》评选出的亚洲35位35岁以下科技创新精英(TR35)中,有一位叫Majid Ebrahimi Warkiani获奖者,他研发的新技术将为癌症的诊断和治疗带来新的希望。Warkiani今年32岁,目前是澳大利亚世界顶尖研究型学府新南威尔士大学(U

PLoS One:CHADS2和CHA2DS2-VASc评分可用于血液透析患者的死亡的预测

背景:CHADS2和CHA2DS2-VASc评分通常用于房颤患者预测卒中的发生,和Charlson合并症指数(CCI)量表常用于发病率的评估。在血液透析患者死亡率的评分系统及比较尚不清楚。研究者旨在评估CHADS2,CHA2DS2-VASc和CCI分数预测血液透析患者的死亡率。方法:利用台湾国家健康保险系统数据(NHIRD)中, 2005年1月号到 2009年12月31,超过20岁开始血液透析的患

J Am Soc Nephrol:HDL胆固醇的流出能力不能预测血透患者心血管发生的风险

高密度脂蛋白(HDL)的保护作用主要是由胆固醇流出能力决定的,这表明肾功能正常人群中HDL与动脉粥样硬化性心血管疾病是负相关的。终末期肾病患者ESRD有异常高的心血管风险,这些风险不能完全由传统的危险因素解释。在这里,对参与德国糖尿病透析研究中的1147例血液透析的2型糖尿病患者进行post-hoc分析,研究者调查高密度脂蛋白胆固醇流出能力是否能预测心血管风险。通过孵化人巨噬细胞消耗血清apoB量